anti-CCR8 monoclonal antibody GS-1811

A humanized immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody GS-1811 targets and binds to CCR8 on CCR8-positive, immunosuppressive tumor-infiltrating T-regulatory (TITR) cells in the tumor microenvironment (TME), and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. GS-1811 depletes CCR8-positive TITR cells via antibody-dependent cell-mediated cytotoxicity (ADCC), which may reactivate antitumor immune responses. CCR8 is specifically expressed by TITR cells in multiple types of cancer and plays a key role in immunosuppression.